Big News: FDA is moving from MasterControl to ComplianceQuest.See Why
Talk to a SpecialistLoading…
Talk to a SpecialistTalk to a SpecialistIndoco Remedies Limited's drug manufacturing facility in Goa, India failed to maintain Current Good Manufacturing Practice (CGMP) standards, resulting in adulterated finished pharmaceutical products. During a July 2024 inspection, investigators identified critical deficiencies in microbiological testing controls, including non-viable dark particles contaminating culture plates and filters, inconsistent media plate preparation, and failure to properly document and justify deviations from required laboratory control mechanisms. These quality control failures created significant risk that microbiological contaminants could go undetected in finished drug products released to market.